908 Devices Announces Closing of Initial Public Offering & Full Exercise of the Underwriters' Option to Purchase Additional S...
2020年12月23日 - 7:23AM
ビジネスワイヤ(英語)
908 Devices Inc., a pioneer of purpose-built handheld and
desktop mass spec devices for chemical and biomolecular analysis,
today announced the closing of its upsized initial public offering
of shares of its common stock, with 7,475,000 shares offered and
sold by the Company at a public offering price of $20.00 per share,
which includes the full exercise of the underwriters’ option to
purchase an additional 975,000 shares of common stock from the
Company. The shares began trading on the Nasdaq Global Market on
December 18, 2020 under the ticker symbol “MASS.”
Cowen and SVB Leerink acted as lead book-running managers for
the proposed offering. William Blair and Stifel acted as
book-running managers for the proposed offering.
A registration statement on Form S-1 relating to the shares sold
in the initial public offering has been filed with the Securities
and Exchange Commission and was declared effective on December 17,
2020. Copies of the final prospectus relating to this offering may
be obtained from: Cowen and Company, LLC, c/o Broadridge Financial
Solutions, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at 833-297-2926, or by
email at PostSaleManualRequests@broadridge.com; or SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, Massachusetts 02120, telephone: 1-800-808-7525, ext. 6132,
or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About 908 Devices
908 Devices is democratizing laboratory mass spectrometry with
its simple handheld and desktop devices, addressing
critical-to-life applications. The Company’s devices are used at
the point-of-need to interrogate unknown and invisible materials
and provide quick, actionable answers to directly address some of
the most critical problems in life sciences research,
bioprocessing, pharma / biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
conducts research, designs and manufactures innovative products
that bring together the power of mass spectrometry, microfluidic
separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking information,”
including with respect to the timing of the initial public offering
and our intended use of proceeds. Words or phrases such as “will,”
“believes,” “intends” or “expects” or similar expressions are
intended to identify forward-looking statements. Forward-looking
statements involve known and unknown risks, uncertainties and
assumptions, including the risks outlined under “Risk Factors” in
the preliminary prospectus and elsewhere in the Company’s filings
with the SEC, which may cause actual results to differ materially
from any results expressed or implied by any forward-looking
statement. Although the Company believes that the expectations
reflected in its forward-looking statements are reasonable, it
cannot guarantee future results. The Company has no obligation, and
does not undertake any obligation, to update or revise any
forward-looking statement made in this press release to reflect
changes since the date of this press release, except as required by
law.
For questions, please contact our Investor Relations team at
IR@908devices.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201222005701/en/
Emily Fang 908Devices@pancomm.com 617-833-9364
908 Devices (NASDAQ:MASS)
過去 株価チャート
から 6 2024 まで 7 2024
908 Devices (NASDAQ:MASS)
過去 株価チャート
から 7 2023 まで 7 2024